| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18830 R80184 |
Kolding (Controls exposed to insulin), 2025 | Large for gestational age (plus 22% (3 p) of registered livebirths) | 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No GLP1-RA indication: Mixed (Diabetes and/or Overweight) or Unspecified |
0.35 [0.12;0.92] excluded (control group) |
6/29 218/514 | 224 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18831 R80191 |
Kolding (Controls unexposed, general pop), 2025 | Large for gestational age (plus 22% (3 p) of registered livebirths) | 1st trimester | retrospective cohort | unexposed (general population or NOS) | Adjustment: No GLP1-RA indication: Mixed (Diabetes and/or Overweight) or Unspecified | 5.94 [1.98;15.02] | 6/29 4,184/99,522 | 4,190 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18784 R79941 |
Maya, 2025 | Large for gestational age birth weight (>90th percentile for gestational age and sex) | 3 months or more before pregnancy or1st trimester excluded | retrospective cohort | unexposed (general population or NOS) | Adjustment: No GLP1-RA indication: Mixed (Diabetes and/or Overweight) or Unspecified Matched |
1.27 [0.82;1.97] excluded (exposition period) |
33/200 78/600 | 111 | 200 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 1 studies | 5.94 [2.16;16.36] | 4,190 | 29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 18830